See ratings and reviews when you sign up for an account.

Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

This study is currently Recruiting

October 2011 By Pfizer

First Recieved on January 19, 2011

Last Updated on October 21, 2011

Sponsor: Pfizer
Information provided by: Pfizer
Identifier: NCT01280747


The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients without such restrictions on pregabalin in a naturalistic setting.

Study Type: Observational
Study Design: Observational Model: Cohort, Time Perspective: Prospective


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - A physician-confirmed diagnosis of either pDPN or FM, but not both. - Initiation of a medication for pDPN or FM is clinically indicated, either as monotherapy or in combination with other treatments, as determined by the treating physician, and agreed to by the patient. - No prior pregabalin use or pregabalin PA requests. Exclusion Criteria: - Age < 18 years at time of study enrollment. - Females or are partners of males currently pregnant/lactating or intending to become pregnant in the next 6 months - Physician-confirmed diagnosis of both pDPN and FM.


  • Investigator: Pfizer Call Center - Study Director - Pfizer


  • Endocrine Associates of Long Island, P.C.

    Smithtown, New York 11787 United States

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.